Drugs / Terriptylimab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07028918 | Aug 2025 → Aug 2026 overdue | oral cavity squamous cell carcinoma | Qilu Hospital of Shandong University | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Terriptylimab | “Terriptylimab: fixed dose 240 mg, q30000, intravenous infusion, each infusion lasting 30 minutes” NCT07028918 ↗ |
| Route | Intravenous | “intravenous infusion” NCT07028918 ↗ |